ReviewJournal of endocrinological investigation2022
Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones.
Review in Journal of endocrinological investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06523530 (Effect of the Pharmacological Cessation of Menstruation With a GnRH Analog on Hepatic Steatosis in Women With Endometriosis), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of the Pharmacological Cessation of Menstruation With a GnRH Analog on Hepatic Steatosis in Women With Endometriosis
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Adiposity and Cumulative Cardiometabolic Risk Factors as Determinants of Hepatic Steatosis Severity in Postmenopausal Women.Journal of clinical medicine · 2026Article
- MASLD, diabetes and PMOS across the female life stages.Diabetologia · 2026Review
- MASLD coexisting with PCOS increases cardiometabolic risk.The Journal of clinical endocrinology and metabolism · 2026Article
- Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri-Menopausal MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Global, regional, and national burden of NAFLD in adults aged 20-49 years (1990-2021): a comprehensive analysis of trends, decomposition, and health inequality.BMC gastroenterology · 2025Article
- Review
- The impact of parity on the risk of nonalcoholic fatty liver disease defined by hepatic steatosis index: A nationwide cohort study.Scientific reports · 2025Article
- Utility of the serum alanine aminotransferase to high density lipoprotein cholesterol ratio in evaluating nonalcoholic fatty liver disease and liver fibrosis.Scientific reports · 2025Article
- Addressing the essentials of the recent guidelines for managing patients with metabolic dysfunction-associated steatotic liver disease.Hormones (Athens, Greece) · 2025Review
- Metabolic dysfunction associated steatotic liver disease is associated with an increased risk of multiple respiratory system diseases.Scientific reports · 2025Article
- Review
- Elevated non-HDL-C to HDL-C ratio as a marker for NAFLD and liver fibrosis risk: a cross-sectional analysis.Frontiers in endocrinology · 2024Article
- 17β-Estradiol (EAntioxidants (Basel, Switzerland) · 2023Article
- Molecular Action of Tamoxifen in the Ovaries of Rats with Mammary Neoplasia.International journal of molecular sciences · 2023Article
- Unraveling the Role of Hepatic PGC1α in Breast Cancer Invasion: A New Target for Therapeutic Intervention?Cells · 2023Article
- Hepatocyte PPARγ contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice.Cellular and molecular life sciences : CMLS · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) differs between various stages of the female lifespan. The aim of this review is to summarize current evidence on the association of NAFLD and circulating sex hormones and to explore the pathogenesis of NAFLD within the context of (1) sex hormone changes during the reproductive, post-reproductive female life and beyond and (2) the in vitro and in vivo evidence on pharmacological modulation in women on menopausal hormone treatment (MHT) or endocrine therapy after breast cancer. The fluctuation in estrogen concentrations, the relative androgen excess, and the age-related reduction in sex hormone-binding globulin are related to increased NAFLD risk. Moreover, the peri-menopausal changes in body composition and insulin resistance might contribute to the increased NAFLD risk. Whether MHT prevents or improves NAFLD in this population remains an open question. Studies in women with breast cancer treated with tamoxifen or non-steroidal aromatase inhibitors point to their adverse effects on NAFLD development, although a more pronounced effect of tamoxifen is reported. Future studies focusing on the underlying pathogenesis should identify subgroups with the highest risk of NAFLD development and progression into more aggressive forms, as well as elucidate the role of hormone therapies, such as MHT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.